Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 19/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 18/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925283 | 0.85 | PIK3CG (0.70) | PIK3CBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL4208518 | 0.85 | PIK3CG (0.59) | PIK3CBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL925850 | 0.80 | PIK3CD (0.64) | PIK3CBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL48419 | 0.78 | PIK3CG (0.73) | PIK3CBPIK3CAPIK3CDPIK3CGXIAP | |
| SCHEMBL12992093 | 0.78 | PIK3CG (0.74) | PIK3CBPIK3CAPIK3CDPIK3CGXIAP | |
| SCHEMBL27597050 | 0.78 | PIK3CA (0.68) | PIK3CBPIK3CAPIK3CDPIK3CGXIAP | |
| SCHEMBL48567 | 0.77 | PIK3CG (0.74) | PIK3CBPIK3CAPIK3CDPIK3CGXIAP | |
| SCHEMBL924694 | 0.77 | PIK3CD (0.67) | PIK3CBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL925427 | 0.77 | PIK3CG (0.56) | PIK3CBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL924785 | 0.77 | PIK3CG (0.56) | PIK3CBPIK3CAPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868188-B2 | 5-heteroaryl thiazoles and their use as PI3K inhibitors | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| EP-1841763-B1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| CN-101098869-A | 5-heteroaryl thiazoles and their use as p13k inhibitors | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | MTOR, PIK3R5, PIK3CA | PIK3CB 18/4885PIK3CA 3/4885PIK3CD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.